Health Care Equipment & Services

Explore how Fulgent Genetics’ CFO’s sell‑to‑cover trades reveal routine tax‑covering moves, not bad news, and what that means for investors.

Insider confidence at NeuroOne spurs hope: execs buy 110k shares on a low‑price day, backing next‑gen StereoCED and potential human trials.

NeuroOne insiders buy 35,000 options, boosting confidence in the company’s StereoCED platform and hinting at potential upside for investors.

Gifford David R’s August 25 sell of 1,779 NHCC shares reveals a tactical divestment, not a bearish bet, amid growing insider buying and a strong earnings beat.

Bruls’ recent 2,644‑share sale at $89.98 reflects a careful, profit‑taking strategy amid Edwards Lifesciences’ rally—what it signals for insiders and investors.

Insider Kittu’s zero‑consideration moves keep his stake stable—no price impact, no shift in confidence. Learn how this routine transfer affects BillionToOne shares.

Discover why President Daniel McCarthy’s recent sale of 65,892 Evolent Health shares may signal a quiet liquidity shift, not distress.

Gilde Healthcare’s steady selling of Shoulder Innovations shares signals gradual dilution amid a 4% weekly slide – investors weigh long‑term resilience against shifting insider ownership.

Bailey Calli Sullivan’s modest insider sale after Nakamoto’s reverse split signals confidence in the merger‑driven growth strategy and potential upside for long‑term investors.

Inside Nakamoto Inc.’s latest insider sales: CFO Teresa Gendron’s strategic sell‑off reflects confidence, liquidity management and a bullish outlook for the company’s healthcare focus.